Taysha showcases new TSHA-102 Rett data

Taysha Gene Therapies, Inc. filed a current report to let investors know it has issued a new press release about its lead Rett syndrome gene therapy candidate, TSHA-102.

Rhea-AI Filing Summary

Taysha Gene Therapies, Inc. filed a current report to let investors know it has issued a new press release about its lead Rett syndrome gene therapy candidate, TSHA-102. The press release, dated October 9, 2025, presents a supplemental data analysis from Part A of the REVEAL Phase 1/2 clinical trials in Rett syndrome, and the data were shared at the 54th Child Neurology Society Annual Meeting.

The full text of this press release is included as Exhibit 99.1 to the report and is incorporated by reference, meaning detailed clinical and scientific information is contained in that exhibit rather than in the body of the report itself.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Taysha Gene Therapies (TSHA) report in this 8-K?

Taysha Gene Therapies reported that it issued a press release presenting a new supplemental data analysis from Part A of the REVEAL Phase 1/2 trials for TSHA-102 in Rett syndrome.

What is TSHA-102 in the context of Taysha Gene Therapies (TSHA)?

TSHA-102 is Taysha Gene Therapies’ gene therapy candidate being studied in the REVEAL Phase 1/2 clinical trials for patients with Rett syndrome.

Where were the new TSHA-102 Rett syndrome data presented by Taysha (TSHA)?

The supplemental data analysis from Part A of the REVEAL Phase 1/2 trials for TSHA-102 in Rett syndrome was presented at the 54th Child Neurology Society Annual Meeting.

How can investors access the detailed TSHA-102 trial data from Taysha (TSHA)?

The detailed information is contained in the press release titled “Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting,” which is attached as Exhibit 99.1.

Does this Taysha Gene Therapies (TSHA) filing include financial results?

No, this report focuses on the issuance of a press release about new clinical trial data for TSHA-102 in Rett syndrome and does not provide financial results.

What exhibits are attached to this Taysha Gene Therapies (TSHA) filing?

The filing includes Exhibit 99.1, the October 9, 2025 press release about TSHA-102 clinical data, and Exhibit 104, the cover page interactive data file.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/09/2025 - 08:24 AM Learn about SEC filing dates

false 0001806310 0001806310 2025-10-09 2025-10-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 9, 2025

Taysha Gene Therapies, Inc.

(Exact name of registrant as specified in its Charter)

Delaware		001-39536		84-3199512
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3000 Pegasus Park Drive, Suite 1430 Dallas, Texas		75247
(Address of Principal Executive Offices)		(Zip Code)

(214) 612-0000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value		TSHA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 9, 2025, Taysha Gene Therapies, Inc. issued a press release entitled “Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated October 9, 2025.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Taysha Gene Therapies, Inc.
				By:		/s/ Kamran Alam
Date: October 9, 2025						Kamran Alam
						Chief Financial Officer